<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1065">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04383548</url>
  </required_header>
  <id_info>
    <org_study_id>Mini-pooled IVIG in COVID19</org_study_id>
    <nct_id>NCT04383548</nct_id>
  </id_info>
  <brief_title>Clinical Study for Efficacy of Anti-Corona VS2 Immunoglobulins Prepared From COVID19 Convalescent Plasma Prepared by VIPS Mini-Pool IVIG Medical Devices in Prevention of SARS-CoV-2 Infection in High Risk Groups as Well as Treatment of Early Cases of COVID19 Patients</brief_title>
  <official_title>Randomized Prospective Clinical Study for Efficacy of Anti-Corona VS2 Immunoglobulins Prepared From COVID19 Convalescent Plasma in Prevention of Infection in High Risk Groups as Well as Treatment of Early Cases of COVID19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preparation of safe purified hyper immunoglobulins containing anti-Corona VS2 immunoglobulins
      from plasma collected from COVID19 convalescent patients to be used to:

        1. To determine efficacy of COVID19 hyper immunoglobulins prepared from convalescent plasma
           using VIPS Mini-Pool IVIG medical device in the treatment of COVID19

        2. To determine efficacy of anti-SARS-CoV-2 hyper immunoglobulins in the prevention of
           infection in high risk groups exposed to SARS-CoV-2 infection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current COVID19 pandemic poses a huge challenge on health authorities and infrastructure
      due to rapid progression of infection with an estimated rate of severe disease that needs
      hospitalization and medical intervention. It is also noteworthy that health care workers are
      at high risk of contracting COVID19 when dealing with cases.

      Previous experience with Corona SARS demonstrated a therapeutic benefit of using convalescent
      plasma for patients with Corona SARS in Hong Kong. Passive immunization using hyper
      immunoglobulin preparations against measles as well as early treatment was proven effective
      when compared to no intervention conservative approach . A recent publication encourages the
      use of COVID19 convalescent serum for the preparation of hyper immunoglobulins to be used for
      passive immunization as well as treatment of early disease before the development of lower
      respiratory tract disease; pneumonia.

      Provision of Convalescent COVID19 hyper immunoglobulin:

      This can be achieved through one of the following three approaches:

      Fist approach: Convalescent COVID19 immunoglobulins can be obtained by transfusion of 1 - 4
      units of COVID19 FFP for passive immunization or treatment of early disease. The advantages
      of this approach is that it is easy to prepare such units of FFP through regular blood banks.
      Disadvantages include variability of existence and levels of neutralizing COVID19
      immunoglobulins in individual plasma units. This may result in variability of effectiveness
      for such an approach for prevention and treatment. Risk of transfusion transmitted infections
      as well as immunological adverse events due to infusion of large volume of FFP are among
      other disadvantages of using individual FFP units.

      Second approach: Classical industrial COVID19 hyper immunoglobulins from convalescent donors.
      This approach provides more consistent small volumes of concentrated hyperimmunoglobulin
      preparations due to pooling of plasma donations from large number of convalescent donors
      which bypasses the variability of neutralizing immunoglobulins in individual plasma
      donations. The preparation of hyper immunoglobulins includes steps for virus inactivation
      which results in safer products compared to non-virally inactivated FFP. Production of
      COVID19 convalescent hyper immunoglobulins under current situation is practically not
      feasible due to limited source COVID19 convalescent plasma, regulatory hurdles and the large
      volume of production batches (minimum of 100s of liters of convalescent plasma).

      Third approach: Recently a Swiss company developed medical device to prepare Intravenous
      Immunoglobulin (IVIG) preparations from only 4 liters of plasma (20 units of FFP) which is
      sufficient to produce 20 grams of IVIG. The technology involves the concentration of
      immunoglobulins from 20 plasma donations into IVIG preparations as well as virus inactivation
      of lipid enveloped viruses (HBV, HCV, HIV &amp; Corona VS2) . Safety of Mini-Pool IVIG was proven
      in a previous clinical trial conducted in ITP pediatric population. The yield of one batch of
      this Mini-Pool IVIG is about 20 gms which can be sufficient for prophylaxis and/or treatment
      of 6 - 10 individuals.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of COVID19 hyper immunoglobulins for patients</measure>
    <time_frame>2 weeks</time_frame>
    <description>efficacy of COVID19 hyper immunoglobulins prepared from convalescent plasma using VIPS Mini-Pool IVIG medical device in the treatment of COVID19</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of COVID19 hyper immunoglobulins for high risk groups</measure>
    <time_frame>1 month</time_frame>
    <description>efficacy of anti-SARS-CoV-2 hyper immunoglobulins in the prevention of infection in high risk groups exposed to SARS-CoV-2 infection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of anti-SARS-CoV-2 hyper immunoglobulins assessed by percentage of adverse events</measure>
    <time_frame>72 hours</time_frame>
    <description>overall percentage of adverse events as hemolysis and anaphylaxis ,headache and other complains that occur during 72 hours of following infusion of anti-SARS-CoV-2 hyper immunoglobulins will be assessed by 1-vital sign 2-hemolysis by LDH and bilirubin level</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID19</condition>
  <arm_group>
    <arm_group_label>Hyper immunoglobulins have anti-Corona VS2 immunoglobulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>safe purified hyper immunoglobulins containing anti-Corona VS2 immunoglobulins from plasma collected from COVID19 convalescent patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>hyper immunoglobulins containing anti-Corona VS2 immunoglobulin</intervention_name>
    <description>Prospective randomized clinical study for efficacy of anti-SARS-CoV-2 hyper immunoglobulins prepared from COVID19 convalescent plasma using VIPS Mini-Pool IVIG medical device</description>
    <arm_group_label>Hyper immunoglobulins have anti-Corona VS2 immunoglobulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        a. Passive immunization group (Group A)

          1. 20 high risk exposed persons (HCPs) who are nasopharyngeal swab SARSCoV-2 PCR negative
             and seronegative for SARS-CoV-2 IgM/IgG antibodies to receive prophylactic anti-
             SARS-CoV-2 hyper immunoglobulin. Selected population can be both male and female with
             age range 21 - 50 years b. 20 high risk persons (HCPs) who are nasopharyngeal swab
             SARS-CoV-2 PCR negative and seronegative for SARS-CoV-2 IgM/IgG antibodies as control
             group. Selected population can be both male and female with age range 21 - 50 years

          2. Patient group (group B):

        a. 30 patients with COVID19 disease and nasopharyngeal swab or sputum SARSCoV-2 positive
        PCR to receive anti-SARS-CoV-2 in addition to applied clinical management protocol.
        Selected test group can be male or female with age &gt;20 years b. 30 patients with COVID-19
        disease and nasopharyngeal swab or sputum SARS-CoV-2 PCR positive managed according to
        applied clinical management protocols of COVID-19 disease as control group. Selected test
        group can be male or female with age &gt;30 years

        Exclusion Criteria:

          1. Passive immunization group (Group A):

               1. Age less than 21 or above 50 years

               2. . Nasopharyngeal swab SARS-CoV-2 positive PCR

               3. . Presence of anti-SARS-CoV-2 IgM, IgG

               4. Presence of comorbidities such as hypertension, diabetes, chronic renal disease,
                  previous thrombotic events or states of allergy such as urticaria or bronchial
                  asthma as well as previous adverse events due to infusion of IVIG

          2. Patient group (group B):

               1. Age less than 20 years

               2. . SARS-CoV-2 PCR negative

               3. . COVID-19 patients who may suffer from co morbidities such as hypertension,
                  diabetes, chronic renal disease, thrombotic tendency or history of adverse events
                  to IVIG as well as old age will be excluded to reduce the possibility of
                  development of serious adverse events related to infusion of IVIG unless it will
                  be for compassionate use in advanced stages of COVID-19 patients and after
                  obtaining informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maha A Mohamed, professor</last_name>
    <role>Study Director</role>
    <affiliation>Assiut univeristy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Magdy El Ekiaby, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sabrawishy hospital,Dokki,Giza,Egypt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Azza M Ez-Eldin, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut univeristy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alia M Hussein, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut univeristy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alshaimaa M Selim, specialist</last_name>
    <phone>01003580480</phone>
    <email>shaimaamokhtargood@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maha A Mohamed, professor</last_name>
    <phone>01000004572</phone>
    <email>atwa_maha@yahoo.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, Chan P, Wong KC, Leung CB, Cheng G. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6.</citation>
    <PMID>15616839</PMID>
  </reference>
  <reference>
    <citation>Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020 Apr;20(4):398-400. doi: 10.1016/S1473-3099(20)30141-9. Epub 2020 Feb 27.</citation>
    <PMID>32113510</PMID>
  </reference>
  <reference>
    <citation>El-Ekiaby M, Sayed MA, Caron C, Burnouf S, El-Sharkawy N, Goubran H, Radosevich M, Goudemand J, Blum D, de Melo L, Souli√© V, Adam J, Burnouf T. Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system. Transfus Med. 2010 Feb;20(1):48-61. doi: 10.1111/j.1365-3148.2009.00963.x. Epub 2009 Sep 23.</citation>
    <PMID>19778318</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 17, 2020</study_first_submitted>
  <study_first_submitted_qc>May 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>May 10, 2020</last_update_submitted>
  <last_update_submitted_qc>May 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Alshaimaa Mokhtar Selim mohamed</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

